Table 1 Number of samples analyzed for each tumor type and stage
From: The prognostic potential of alternative transcript isoforms across human tumors
T | N | M | S | ||||||
|---|---|---|---|---|---|---|---|---|---|
Tumor type | Acronym | Early | Late | Early | Late | Early | Late | Early | Late |
Breast invasive carcinoma | BRCA | 256 (T1) | 147 (T3, T4) | 455 (N0) | 171 (N2, N3) | 836 (M0) | 15 (M1) | 164 (S1) | 15 (S4) |
Colon adenocarcinoma | COAD | 45 (T1, T2) | 31 (T4) | 149 (N0) | 39 (N2) | 179 (M0) | 33 (M1) | 40 (S1) | 34 (S4) |
Head and neck squamous cell carcinoma | HNSC | 35 (T1) | 110 (T4) | 166 (N0) | 166 (N2, N3) | 77 (S1, S2) | 169 (S4) | ||
Kidney chromophobe | KICH | 20 (T1) | 19 (T3, T4) | 20 (S1) | 19 (S3, S4) | ||||
Kidney renal clear cell carcinoma | KIRC | 245 (T1) | 186 (T3, T4) | 233 (N0) | 16 (N1) | 419 (M0) | 77 (M1) | 240 (S1) | 78 (S4) |
Kidney renal papillary carcinoma | KIRP | 71 (T1) | 38 (T3, T4) | 23 (N0) | 16 (N1, N2) | 66 (S1) | 38 (S3, S4) | ||
Lung squamous cell carcinoma | LUSC | 93 (T1) | 59 (T3, T4) | 242 (N0) | 37 (N2, N3) | 195 (S1) | 76 (S3, S4) | ||
Lung adenocarcinoma | LUAD | 137 (T1) | 57 (T3, T4) | 281 (N0) | 70 (N2, N3) | 307 (M0) | 22 (M1) | 99 (S1) | 242 (S3, S4) |
Ovarian serous cystadenocarcinoma | OV | 18 (S2) | 243 (S4) | ||||||
Prostate adenocarcinoma | PRAD | 69 (T2) | 93 (T3, T4) | 129 (N0) | 14 (N1) | ||||
Skin cutaneous melanoma | SKCM | 68 (M0) | 17 (M1) | ||||||
Thyroid carcinoma | THCA | 137 (T1) | 179 (T3, T4) | 220 (N0) | 211 (N1) | 270 (S1) | 48 (S4) | ||